newsfilter
← Latest News
ACCESS Newswire·

Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results

Expanded strategic partnership with The Scripps Research Institute to advance proof-of-concept studies and further develop its program combining systemic DNase I with CAR T-cell therapiesEnded the quarter with $4.8